Cong-Hui Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Cong-Hui Han has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
Lin Hao
Department of Urology, Xuzhou Central Hospital Affiliated Central Hospital of Xuzhou Medical University Xuzhou Jiangsu China
24 shared publicationsKun Pang
Department of Urology, Xuzhou Central Hospital, Xuzhou, China
20 shared publicationsYang Dong
Department of Urology, Xuzhou Central Hospital Affiliated to Nanjing University of Chinese Medicine , Xuzhou , Jiangsu , China
17 shared publicationsZhen-Duo Shi
Department of Urology Xuzhou Central Hospital Xuzhou China
16 shared publications- Zhe-Sheng Chen
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, New York, USA
9 shared publications Zhenduo Shi
Xuzhou Cent Hosp, Dept Urol, Xuzhou 221009, Jiangsu, Peoples R China
8 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Influence of Male Body Mass Index on Sperm Quality and In Vitro Fertilization Success Rates
Sun Q, et al. World J Mens Health. 2026 ;44:e22. https://doi.org/10.5534/wjmh.250191
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Open AccessInfluence of Male Body Mass Index on Sperm Quality and In Vitro Fertilization Success Rates
Sun Q, et al. World J Mens Health. 2026 ;44:e22. https://doi.org/10.5534/wjmh.250191
- Open Access
- 1 April 2025
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 19 (2) , 94-105
Exploring the molecular mechanism of Xiao Ji ( Cirsium setosum ) in treating bladder cancer using network pharmacology and molecular docking
Background: In China, Xiao Ji decoction has been used to treat hematuria. However, pharmacological studies on its effects against bladder cancer (BC) remain limited. Objective: This study aims to explore the potential mechanisms of Xiao Ji in treating BC using network pharmacology and molecular docking. Methods: The active constituents of Xiao Ji and their corresponding molecular targets were identified through the utilization of the Traditional Chinese Medicine Systems Pharmacology Database. Genes associated with BC were screened by employing resources including the Online Mendelian Inheritance in Man (OMIM) and GeneCards databases. Furthermore, protein–protein interaction (PPI) networks and networks illustrating the connections between ingredients and their ingredient–target (I–T) were established. The related genes underwent gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Ultimately, molecular docking experiments were conducted to substantiate and reinforce the proposed hypotheses. Results: Four compounds were identified, along with 82 target genes that exhibited associations with BC. In the I–T network, quercetin exhibited the highest degree of association with multiple targets. Within the PPI network, interleukin (IL)IL-6, hypoxia inducible factor 1 subunit alpha (HIF1A), epidermal growth factor receptor (EGFR), and myelocytomatosis oncogene (MYC) were discerned as pivotal genes. The enrichment analysis of the critical genes led to the identification of 92 GO terms and 105 pathways. Furthermore, the results of molecular docking analyses revealed that the active compounds, including acacetin, sitosterol, and stigmasterol, exhibited strong binding affinities with IL-6, EGFR, and MYC. Conclusions: Xiao Ji acts on BC through multiple targets and pathways. This study elucidates the potential mechanisms of Xiao Ji in treating BC, providing new options for BC therapy.
- 1 April 2025
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 19 (2) , 94-105
Open AccessExploring the molecular mechanism of Xiao Ji ( Cirsium setosum ) in treating bladder cancer using network pharmacology and molecular docking
Background: In China, Xiao Ji decoction has been used to treat hematuria. However, pharmacological studies on its effects against bladder cancer (BC) remain limited. Objective: This study aims to explore the potential mechanisms of Xiao Ji in treating BC using network pharmacology and molecular docking. Methods: The active constituents of Xiao Ji and their corresponding molecular targets were identified through the utilization of the Traditional Chinese Medicine Systems Pharmacology Database. Genes associated with BC were screened by employing resources including the Online Mendelian Inheritance in Man (OMIM) and GeneCards databases. Furthermore, protein–protein interaction (PPI) networks and networks illustrating the connections between ingredients and their ingredient–target (I–T) were established. The related genes underwent gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Ultimately, molecular docking experiments were conducted to substantiate and reinforce the proposed hypotheses. Results: Four compounds were identified, along with 82 target genes that exhibited associations with BC. In the I–T network, quercetin exhibited the highest degree of association with multiple targets. Within the PPI network, interleukin (IL)IL-6, hypoxia inducible factor 1 subunit alpha (HIF1A), epidermal growth factor receptor (EGFR), and myelocytomatosis oncogene (MYC) were discerned as pivotal genes. The enrichment analysis of the critical genes led to the identification of 92 GO terms and 105 pathways. Furthermore, the results of molecular docking analyses revealed that the active compounds, including acacetin, sitosterol, and stigmasterol, exhibited strong binding affinities with IL-6, EGFR, and MYC. Conclusions: Xiao Ji acts on BC through multiple targets and pathways. This study elucidates the potential mechanisms of Xiao Ji in treating BC, providing new options for BC therapy.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 31 (3) , 219-232
Inhibition of Colorectal Cancer Metastasis by Total Flavones of Abelmoschus manihot via LncRNA AL137782-mediated STAT3/EMT Pathway Regulation
Background: Colorectal cancer (CRC) ranks among the most lethal malignancies globally, particularly following metastasis which results in poor prognosis. In recent years, CRC incidence in China has persistently increased. Total flavonoids (TFA) from Abelmoschus manihot, a natural compound, are recognized for their anti-inflammatory, analgesic, and antioxidant properties. However, despite extensive research into the therapeutic potential of TFA, coverage of its role in cancer treatment is notably lacking. To address this research void, our study aims to unveil the role and potential mechanisms of TFA in treating CRC. Methods: We conducted a series of experiments to assess the impact of TFA on CRC cells. Two specific CRC cell lines, DLD-1 and HCT116, were employed in cell proliferation, colony formation, flow cytometry, and cell migration assays. Additionally, to test the in vivo effects of TFA, we developed a nude mouse xenograft tumor model to assess TFA's impact on tumor growth and liver metastasis. Furthermore, we meticulously analyzed the gene expression differences between CRC cells pretreated with TGF-β and those treated with TFA using RNA-seq technology. We also examined the molecular mechanisms of TFA and assessed the expression of proteins related to the STAT3/EMT signaling pathway through Western blotting and siRNA technology. Results: Our research findings reveal for the first time the effect of TFA on CRC cells. Result shows that TFA could suppress cell proliferation, migration, and induce apoptosis. In vivo results showed that TFA inhibited tumor growth and liver metastasis. Molecular mechanism studies have shown that TFA exerts these effects by upregulating the expression of non-coding RNA AL137782, inhibiting the EMT/STAT3 signaling pathway. These results suggest that TFA is a potential candidate for mitigating CRC metastasis. Conclusion: However, further research is needed to comprehensively evaluate the efficacy and safety of TFA in animal models and clinical settings. These findings bring great hope for the development of innovative CRC treatment methods.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 31 (3) , 219-232
Inhibition of Colorectal Cancer Metastasis by Total Flavones of Abelmoschus manihot via LncRNA AL137782-mediated STAT3/EMT Pathway Regulation
Background: Colorectal cancer (CRC) ranks among the most lethal malignancies globally, particularly following metastasis which results in poor prognosis. In recent years, CRC incidence in China has persistently increased. Total flavonoids (TFA) from Abelmoschus manihot, a natural compound, are recognized for their anti-inflammatory, analgesic, and antioxidant properties. However, despite extensive research into the therapeutic potential of TFA, coverage of its role in cancer treatment is notably lacking. To address this research void, our study aims to unveil the role and potential mechanisms of TFA in treating CRC. Methods: We conducted a series of experiments to assess the impact of TFA on CRC cells. Two specific CRC cell lines, DLD-1 and HCT116, were employed in cell proliferation, colony formation, flow cytometry, and cell migration assays. Additionally, to test the in vivo effects of TFA, we developed a nude mouse xenograft tumor model to assess TFA's impact on tumor growth and liver metastasis. Furthermore, we meticulously analyzed the gene expression differences between CRC cells pretreated with TGF-β and those treated with TFA using RNA-seq technology. We also examined the molecular mechanisms of TFA and assessed the expression of proteins related to the STAT3/EMT signaling pathway through Western blotting and siRNA technology. Results: Our research findings reveal for the first time the effect of TFA on CRC cells. Result shows that TFA could suppress cell proliferation, migration, and induce apoptosis. In vivo results showed that TFA inhibited tumor growth and liver metastasis. Molecular mechanism studies have shown that TFA exerts these effects by upregulating the expression of non-coding RNA AL137782, inhibiting the EMT/STAT3 signaling pathway. These results suggest that TFA is a potential candidate for mitigating CRC metastasis. Conclusion: However, further research is needed to comprehensively evaluate the efficacy and safety of TFA in animal models and clinical settings. These findings bring great hope for the development of innovative CRC treatment methods.
- Open Access
- 1 September 2024
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 16, 1573-1581
Prediction of Unexplained Recurrent Miscarriages Using Thromboelastography
Objective: This study investigates the thromboelastography (TEG) changes in patients with unexplained recurrent spontaneous abortion (URSA) to identify effective diagnostic markers for URSA. Methods: We retrospectively analyzed 160 URSA patients from the Gynecology Department of the First People’s Hospital of Lianyungang (June 2017 - June 2020) and compared them with 190 healthy, fertile women without adverse pregnancy histories (control group). TEG parameters were assessed using logistic regression, applying stepwise selection for model optimization. Model performance was evaluated using Receiver Operating Characteristic (ROC) curves, determining sensitivity and specificity. The Youden index identified optimal cut points for predictive probabilities. Results: Significant differences were observed between the URSA and control groups in coagulation reaction time (R), clot formation time (K), clot formation rate (Angle-α), and maximum clot strength (MA) (P< 0.05). Multivariable logistic regression identified R, Angle-α, and MA as independent URSA risk factors. The model demonstrated excellent discrimination (AUC: 0.940; 95% CI: 0.918– 0.962). The optimal cut point of predictive probability (Youden index) was P=0.355, yielding a sensitivity of 0.925 and specificity of 0.795. Conclusion: URSA patients exhibit a hypercoagulable state even when not pregnant. More research is needed to validate our findings and explore the potential clinical implications of anticoagulants in treating URSA.
- 1 September 2024
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 16, 1573-1581
Open AccessPrediction of Unexplained Recurrent Miscarriages Using Thromboelastography
Objective: This study investigates the thromboelastography (TEG) changes in patients with unexplained recurrent spontaneous abortion (URSA) to identify effective diagnostic markers for URSA. Methods: We retrospectively analyzed 160 URSA patients from the Gynecology Department of the First People’s Hospital of Lianyungang (June 2017 - June 2020) and compared them with 190 healthy, fertile women without adverse pregnancy histories (control group). TEG parameters were assessed using logistic regression, applying stepwise selection for model optimization. Model performance was evaluated using Receiver Operating Characteristic (ROC) curves, determining sensitivity and specificity. The Youden index identified optimal cut points for predictive probabilities. Results: Significant differences were observed between the URSA and control groups in coagulation reaction time (R), clot formation time (K), clot formation rate (Angle-α), and maximum clot strength (MA) (P< 0.05). Multivariable logistic regression identified R, Angle-α, and MA as independent URSA risk factors. The model demonstrated excellent discrimination (AUC: 0.940; 95% CI: 0.918– 0.962). The optimal cut point of predictive probability (Youden index) was P=0.355, yielding a sensitivity of 0.925 and specificity of 0.795. Conclusion: URSA patients exhibit a hypercoagulable state even when not pregnant. More research is needed to validate our findings and explore the potential clinical implications of anticoagulants in treating URSA.
- 19 August 2024
- Published by Springer Nature in Science China Life Sciences
- Vol. 67 (12) , 2774-2776
New insights shed light on the enigma of genetic diversity and species complexity
- 19 August 2024
- Published by Springer Nature in Science China Life Sciences
- Vol. 67 (12) , 2774-2776
New insights shed light on the enigma of genetic diversity and species complexity
- Open Access
- 9 June 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (11) , e18410
Troponin T1 in tumorigenesis and immune modulation: Insights into multiple cancers and kidney renal clear cell carcinoma
Troponin T1 (TNNT1) plays a crucial role in muscle contraction but its role in cancer, particularly in kidney renal clear cell carcinoma (KIRC), is not well‐understood. This study explores the expression, clinical significance and biological functions of TNNT1 in various cancers, with an emphasis on its involvement in KIRC. We analysed TNNT1 expression in cancers using databases like TCGA and GTEx, assessing its prognostic value, mutation patterns, methylation status and functional implications. The study also examined TNNT1's effect on the tumour microenvironment and drug sensitivity in KIRC, complemented by in vitro TNNT1 knockdown experiments in KIRC cells. TNNT1 is overexpressed in several cancers and linked to adverse outcomes, showing frequent upregulation mutations and abnormal methylation. Functionally, TNNT1 connects to muscle and cancer pathways, affects immune infiltration and drug responses, and its overexpression in KIRC is associated with advanced disease and reduced survival. Knocking down TNNT1 curbed KIRC cell growth. TNNT1's aberrant expression plays a significant role in tumorigenesis and immune modulation, highlighting its value as a prognostic biomarker and a potential therapeutic target in KIRC and other cancers. Further studies are essential to understand TNNT1's oncogenic mechanisms in KIRC.
- 9 June 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (11) , e18410
Open AccessTroponin T1 in tumorigenesis and immune modulation: Insights into multiple cancers and kidney renal clear cell carcinoma
Troponin T1 (TNNT1) plays a crucial role in muscle contraction but its role in cancer, particularly in kidney renal clear cell carcinoma (KIRC), is not well‐understood. This study explores the expression, clinical significance and biological functions of TNNT1 in various cancers, with an emphasis on its involvement in KIRC. We analysed TNNT1 expression in cancers using databases like TCGA and GTEx, assessing its prognostic value, mutation patterns, methylation status and functional implications. The study also examined TNNT1's effect on the tumour microenvironment and drug sensitivity in KIRC, complemented by in vitro TNNT1 knockdown experiments in KIRC cells. TNNT1 is overexpressed in several cancers and linked to adverse outcomes, showing frequent upregulation mutations and abnormal methylation. Functionally, TNNT1 connects to muscle and cancer pathways, affects immune infiltration and drug responses, and its overexpression in KIRC is associated with advanced disease and reduced survival. Knocking down TNNT1 curbed KIRC cell growth. TNNT1's aberrant expression plays a significant role in tumorigenesis and immune modulation, highlighting its value as a prognostic biomarker and a potential therapeutic target in KIRC and other cancers. Further studies are essential to understand TNNT1's oncogenic mechanisms in KIRC.
- Open Access
- 22 May 2024
- Published by Springer Nature in BMC Urology
- Vol. 24 (1) , 1-11
Clinical characteristics and molecular mechanisms underlying bladder cancer in individuals with spinal cord injury: a systematic review
Background: Patients with spinal cord injury have a relatively high risk for bladder cancer and often complicated with bladder cancer in advanced stages, and the degree of aggressiveness of malignancy is high. Most of the literature is based on disease clinical features while, our study reviews the clinical characteristics and molecular mechanisms of spinal cord injury patients with bladder cancer, so that it might help clinicians better recognize and manage these patients. Method: We searched PubMed, Web of Science and Embase, using retrieval type like (“Neurogenic Lower Urinary Tract Dysfunction” OR “Spinal cord injury” OR “Spinal Cord Trauma”) AND (“bladder cancer” OR “bladder neoplasm” OR “bladder carcinoma” OR “Urinary Bladder Neoplasms” OR “Bladder Tumor”). In Web of Science, the retrieval type was searched as “Topic”, and in PubMed and Embase, as “All Field”. The methodological quality of eligible studies and their risk of bias were assessed using the Newcastle-Ottawa scale. This article is registered in PROSPERO with the CBD number: CRD42024508514. Result: In WOS, we searched 219 related papers, in PubMed, 122 and in Embase, 363. Thus, a total of 254 articles were included after passing the screening, within a time range between 1960 and 2023. A comprehensive analysis of the data showed that the mortality and incidence rates of bladder cancer in spinal cord injury patients were higher than that of the general population, and the most frequent pathological type was squamous cell carcinoma. In parallel to long-term urinary tract infection and indwelling catheterization, the role of molecules such as NO, MiR 1949 and Rb 1. was found to be crucial pathogenetically. Conclusion: This review highlights the risk of bladder cancer in SCI patients, comprehensively addressing the clinical characteristics and related molecular mechanisms. However, given that there are few studies on the molecular mechanisms of bladder cancer in spinal cord injury, further research is needed to expand the understanding of the disease.
- 22 May 2024
- Published by Springer Nature in BMC Urology
- Vol. 24 (1) , 1-11
Open AccessClinical characteristics and molecular mechanisms underlying bladder cancer in individuals with spinal cord injury: a systematic review
Background: Patients with spinal cord injury have a relatively high risk for bladder cancer and often complicated with bladder cancer in advanced stages, and the degree of aggressiveness of malignancy is high. Most of the literature is based on disease clinical features while, our study reviews the clinical characteristics and molecular mechanisms of spinal cord injury patients with bladder cancer, so that it might help clinicians better recognize and manage these patients. Method: We searched PubMed, Web of Science and Embase, using retrieval type like (“Neurogenic Lower Urinary Tract Dysfunction” OR “Spinal cord injury” OR “Spinal Cord Trauma”) AND (“bladder cancer” OR “bladder neoplasm” OR “bladder carcinoma” OR “Urinary Bladder Neoplasms” OR “Bladder Tumor”). In Web of Science, the retrieval type was searched as “Topic”, and in PubMed and Embase, as “All Field”. The methodological quality of eligible studies and their risk of bias were assessed using the Newcastle-Ottawa scale. This article is registered in PROSPERO with the CBD number: CRD42024508514. Result: In WOS, we searched 219 related papers, in PubMed, 122 and in Embase, 363. Thus, a total of 254 articles were included after passing the screening, within a time range between 1960 and 2023. A comprehensive analysis of the data showed that the mortality and incidence rates of bladder cancer in spinal cord injury patients were higher than that of the general population, and the most frequent pathological type was squamous cell carcinoma. In parallel to long-term urinary tract infection and indwelling catheterization, the role of molecules such as NO, MiR 1949 and Rb 1. was found to be crucial pathogenetically. Conclusion: This review highlights the risk of bladder cancer in SCI patients, comprehensively addressing the clinical characteristics and related molecular mechanisms. However, given that there are few studies on the molecular mechanisms of bladder cancer in spinal cord injury, further research is needed to expand the understanding of the disease.
- Open Access
- 1 May 2024
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 13 (5) , 812-827
Exploring the microRNA-mRNA regulatory network associated with solasonine in bladder cancer
Background: Solasonine has been demonstrated to exert an inhibitory effect on bladder cancer (BC), but the potential mechanisms remain unclear. Therefore, the aim of this study is to explore the association between microRNAs (miRNAs)-mediated regulation and the anti-tumor activities of solasonine in BC. Methods: MiRNA sequencing was performed to identify the differentially expressed microRNAs (DE-miRNAs) associated with solasonine in BC cells. Functional enrichment analyses of the DE-miRNAs activated and inhibited by solasonine were then conducted. The DE-miRNAs with prognostic value for BC and those differentially expressed in the BC samples were subsequently identified as the hub DE-miRNAs. After identifying the messenger RNAs (mRNAs) that were targeted by the hub DE-miRNAs and those differentially expressed in the BC samples, a protein-protein interaction analysis was performed to identify the core downstream genes, which were then used to construct a solasonine-miRNA-mRNA regulatory network. Results: A total of 27 activated and 19 inhibited solasonine-mediated DE-miRNAs were identified that were found to be associated with several tumor-related biological functions and pathways. After integrating the results of the survival analysis and expression assessment, the following nine hub DE-miRNAs were identified: hsa-miR-127-3p, hsa-miR-450b-5p, hsa-miR-99a-5p, hsa-miR-197-3p, hsa-miR-423-3p, hsa-miR-4326, hsa-miR-625-3p, hsa-miR-625-5p, and hsa-miR-92a-3p. The DE-mRNAs targeted by the hub DE-miRNAs were predicted, and 30 core downstream genes were used to construct the solasonine-miRNA-mRNA regulatory network. miR-450b-5p was shown to be associated with the most mRNAs in this network, which suggests that it plays a crucial role in the solasonine-mediated anti-BC effect. Conclusions: A regulatory network, including solasonine, miRNAs, and mRNAs related to BC, was constructed. This network provides extensive insights into the molecular regulatory mechanisms that underlie the anti-cancer efficacy of solasonine in BC.
- 1 May 2024
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 13 (5) , 812-827
Open AccessExploring the microRNA-mRNA regulatory network associated with solasonine in bladder cancer
Background: Solasonine has been demonstrated to exert an inhibitory effect on bladder cancer (BC), but the potential mechanisms remain unclear. Therefore, the aim of this study is to explore the association between microRNAs (miRNAs)-mediated regulation and the anti-tumor activities of solasonine in BC. Methods: MiRNA sequencing was performed to identify the differentially expressed microRNAs (DE-miRNAs) associated with solasonine in BC cells. Functional enrichment analyses of the DE-miRNAs activated and inhibited by solasonine were then conducted. The DE-miRNAs with prognostic value for BC and those differentially expressed in the BC samples were subsequently identified as the hub DE-miRNAs. After identifying the messenger RNAs (mRNAs) that were targeted by the hub DE-miRNAs and those differentially expressed in the BC samples, a protein-protein interaction analysis was performed to identify the core downstream genes, which were then used to construct a solasonine-miRNA-mRNA regulatory network. Results: A total of 27 activated and 19 inhibited solasonine-mediated DE-miRNAs were identified that were found to be associated with several tumor-related biological functions and pathways. After integrating the results of the survival analysis and expression assessment, the following nine hub DE-miRNAs were identified: hsa-miR-127-3p, hsa-miR-450b-5p, hsa-miR-99a-5p, hsa-miR-197-3p, hsa-miR-423-3p, hsa-miR-4326, hsa-miR-625-3p, hsa-miR-625-5p, and hsa-miR-92a-3p. The DE-mRNAs targeted by the hub DE-miRNAs were predicted, and 30 core downstream genes were used to construct the solasonine-miRNA-mRNA regulatory network. miR-450b-5p was shown to be associated with the most mRNAs in this network, which suggests that it plays a crucial role in the solasonine-mediated anti-BC effect. Conclusions: A regulatory network, including solasonine, miRNAs, and mRNAs related to BC, was constructed. This network provides extensive insights into the molecular regulatory mechanisms that underlie the anti-cancer efficacy of solasonine in BC.
- Open Access
- 23 March 2024
- Published by Springer Nature in BioDrugs
- Vol. 38 (3) , 353-367
Research Advances in Stem Cell Therapy for Erectile Dysfunction
Erectile dysfunction (ED) is a common clinical condition that mainly affects men aged over 40 years. Various causes contribute to the progression of ED, including pelvic nerve injury, diabetes, metabolic syndrome, age, Peyronie’s disease, smoking, and psychological disorders. Current treatments for ED are limited to symptom relief and do not address the root cause. Stem cells, with their powerful ability to proliferate and differentiate, are a promising approach for the treatment of male ED and are gradually gaining widespread attention. Current uses for treating ED have been studied primarily in experimental animals, with most studies observing improvements in erectile quality as well as improvements in erectile tissue. However, research on stem cell therapy for human ED is still limited. This article summarizes the recent literature on basic stem cell research on ED, including cavernous nerve injury, aging, diabetes, and sclerosing penile disease, and describes mechanisms of action and therapeutic effects of various stem cell therapies in experimental animals. Stem cells are also believed to interact with host tissue in a paracrine manner, and improved function can be supported through both implantation and paracrine factors. To date, stem cells have shown some preliminary promising results in animal and human models of ED.
- 23 March 2024
- Published by Springer Nature in BioDrugs
- Vol. 38 (3) , 353-367
Open AccessResearch Advances in Stem Cell Therapy for Erectile Dysfunction
Erectile dysfunction (ED) is a common clinical condition that mainly affects men aged over 40 years. Various causes contribute to the progression of ED, including pelvic nerve injury, diabetes, metabolic syndrome, age, Peyronie’s disease, smoking, and psychological disorders. Current treatments for ED are limited to symptom relief and do not address the root cause. Stem cells, with their powerful ability to proliferate and differentiate, are a promising approach for the treatment of male ED and are gradually gaining widespread attention. Current uses for treating ED have been studied primarily in experimental animals, with most studies observing improvements in erectile quality as well as improvements in erectile tissue. However, research on stem cell therapy for human ED is still limited. This article summarizes the recent literature on basic stem cell research on ED, including cavernous nerve injury, aging, diabetes, and sclerosing penile disease, and describes mechanisms of action and therapeutic effects of various stem cell therapies in experimental animals. Stem cells are also believed to interact with host tissue in a paracrine manner, and improved function can be supported through both implantation and paracrine factors. To date, stem cells have shown some preliminary promising results in animal and human models of ED.